Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors

Peking University

Status and phase: Completed; Phase 4

Conditions: Hematopoietic Stem Cell Transplantation

Treatments: Drug: post-transplantation cyclophosphamide

Study type: Interventional

Funder types: Other

Identifiers

NCT02412423

2015PHB016-01

Details and patient eligibility

About

In "beijing model" for haploidentical transplant, the rate of acute graft-versus-host disease (GVHD) from maternal or collateral donors was significantly higher than that from other kins. To reduce the GVHD incidence from maternal or collateral donors, post-transplantation cyclophosphamide is planned to be added into the protocol in "beijing model".

Enrollment: 30 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• haploidentical patients from maternal or collateral donors

Exclusion criteria

• uncontrolled infection before transplant

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

treatment group

Experimental group

Description:

post-transplantation cyclophosphamide

Treatment:

Drug: post-transplantation cyclophosphamide